AIM: A gluten- and casein-free diet is often given to @entity1 with @entity72 ( @entity72 ). We aimed to determine the effect of gluten and casein supplementation on maladaptive behaviour, gastrointestinal symptom severity and @entity1630 ( @entity1630 ) excretion in @entity1 with @entity72 . METHODS: A randomised, controlled, double-blind trial was performed on 74 @entity1 with @entity72 with severe maladaptive behaviour and increased urinary @entity1630 . Subjects were randomised to receive gluten-casein or a placebo for seven days. We evaluated maladaptive behaviour before and after supplementation, using @entity1630 excretion, the approach withdrawal problem composite subtest of the @entity245 Behavior Inventory and the Gastrointestinal Symptom Severity Index. RESULTS: The mean approach withdrawal problem composite score was significantly higher before supplementation than after, both in the placebo and in the gluten-casein group. However, the mean difference was not significant and may have been caused by additional therapy. There was no significant difference in gastrointestinal symptoms and urinary @entity1630 excretion. CONCLUSION: Administrating gluten-casein to @entity1 with @entity72 for one week did not increase maladaptive behaviour, gastrointestinal symptom severity or urinary @entity1630 excretion. The effect of prolonged administration or other mechanisms of enterocyte damage in @entity72 should be explored.

Gluten and casein supplementation does not increase symptoms in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['children'] @entity72 :: ('MESH:D002659', 'Disease') :: ['ASD', 'autism spectrum disorder'] @entity245 :: ('MESH:D002658', 'Disease') :: ['Pervasive Developmental Disorder'] @entity1630 :: ('2169', 'Gene') :: ['I-FABP', 'intestinal fatty acids binding protein']
@entity72 :: (MESH:D002659,Disease) :: ['autism spectrum disorder']
